Fianlimab/cemiplimab for melanoma (HARMONY)

Fianlimab+cemiplimab Phase 2 data in advanced melanoma showed ORR ~61-63%, materially above Opdualag's ~43% ORR in RELATIVITY-047. HARMONY is a head-to-head Phase 3 using ORR by BICR as primary endpoint, which favors fianlimab given the Phase 2 benchmark gap. Risks: Phase 2 was single-arm/cross-trial comparison, patient population differences, and prior anti-LAG3 combos have underwhelmed in randomized settings. Still, ORR is a relatively achievable bar.

Phase 3 commitment and a clean, centrally reviewed RECIST ORR endpoint support success, but the approved active-combination comparator sets a demanding efficacy bar. Recruiting status, 451 days to primary completion, and no provided prior efficacy data add execution and disclosure uncertainty.

This is a recruiting Phase 3 active-comparator study against an approved doublet, so the bar is meaningful. BICR-assessed ORR is an objective, relatively early efficacy endpoint, but no prior efficacy data, sample size, effect target, stratification, or interim evidence are provided. The long follow-up window adds execution and disclosure uncertainty.

Phase 3 design, active randomized comparator, and blinded independent central review support a credible efficacy readout. However, the comparator is an approved melanoma regimen, the trial is still recruiting with primary completion in 2027, and the supplied fields provide no efficacy signal or effect-size margin. ORR is objective but can be sensitive to population and threshold definition.

Phase 3 head-to-head vs approved LAG-3+PD-1 (Opdualag) in melanoma; ORR by BICR primary endpoint; recruiting with 2027 completion (451 days); similar mechanism suggests modest differentiation risk; no prior ORR data or powering details in protocol summary.

HARMONY aims to show superiority of fianlimab+cemiplimab over relatlimab+nivolumab on ORR by BICR. While phase 1 fianlimab data showed ~61% ORR, this was investigator-assessed, compared to Opdualag's 43% BICR ORR. Proving superiority against the same MOA (PD-1/LAG-3) is risky; phase 2 ORRs often shrink 10-15% in phase 3 under BICR. If ORR drops to ~50%, superiority will likely fail.

Phase‑3 head‑to‑head of fianlimab+cemiplimab vs approved relatlimab+nivolumab. Both arms use PD‑1 blockade; adding two PD‑1 antibodies may not improve ORR and could raise toxicity. No prior data on fianlimab, trial still recruiting, so modest chance of outperforming benchmark. Estimated ~45% chance of a positive ORR result.

Phase 3 HARMONY compares two LAG-3+PD-1 doublets (fianlimab+cemiplimab vs relatlimab+nivolumab). Primary endpoint is ORR, a softer endpoint than PFS/OS. Two active regimens make it hard to demonstrate clear ORR superiority; statistical powering between similar-mechanism combos is challenging. Trial still recruiting, ~451 days to primary completion, no preliminary data. Some upside if fianlimab shows differentiated binding, but ORR is not the FDA-preferred endpoint and small absolute differences may not reach significance. Modest downside skew.